Blockade of CD49d using specific antibody (Natalizumab) sensitized resistant ALL to chemotherapy, underscoring the potential of α4 integrin targeting therapies as an avenue to abolish the chemoprotective effect of the microenvironment on ALL cells[5]. This evidence concerns the gene ITGA4 and acute lymphoblastic leukemia.